KLOW is a four-component research blend: the three peptides in GLOW, with KPV added. It is supplied for laboratory research use only, and each component is described separately below.
KLOW takes the GLOW combination — GHK-Cu, BPC-157 and TB-500 — and adds 10mg of KPV, a tripeptide corresponding to the C-terminal fragment of α-melanocyte stimulating hormone. The amounts of the other three components are unchanged.
KPV is of interest in preclinical inflammation research, particularly in gastrointestinal models, where it has been studied as a fragment that retains some activity of the parent hormone without its pigmentary effects.
As with GLOW, the combination itself has not been studied under controlled conditions. The component literature should not be read as evidence about the blend.
KPV (lysine-proline-valine) is the C-terminal tripeptide of α-MSH. Preclinical work has examined its effects on inflammatory signalling pathways in cell and rodent models, with particular attention to intestinal epithelium. Unlike the full α-MSH sequence, it is not associated with melanocortin-driven pigmentation.
GHK binds copper(II) with high affinity and is studied in relation to extracellular matrix components and copper transport, largely in cell culture and topical formulation research.
Both are studied in preclinical tissue models — BPC-157 in angiogenic signalling and cell migration, TB-500 in actin polymerisation and cell motility. Neither has human efficacy data.
Batch documentation for KLOW is available on request where we hold it. We do not publish a public batch database, and no purity, identity, sterility or manufacturing claim is stated anywhere on this site unless documentation for that exact batch supports it. To ask what is held for a particular lot, contact us.
These are starting points for your own reading, not endorsements of any conclusion.
KLOW is GLOW with KPV 10mg added — 80mg total rather than 70mg. The GHK-Cu, BPC-157 and TB-500 amounts are identical across both.
KPV is the C-terminal tripeptide of α-melanocyte stimulating hormone, made up of lysine, proline and valine. It is studied in preclinical inflammation research.
KPV is not associated with the melanocortin receptor-driven pigmentation seen with full α-MSH analogues. It is a different fragment with a different research profile.
No. There are no controlled clinical trials of this combination, and we make no claim about it beyond describing its components.
This product is supplied strictly for in-vitro laboratory research. It is not a medicine, is not licensed by the MHRA, and is not for human or veterinary consumption or administration. We do not supply dosing, reconstitution or administration guidance, and nothing on this page is a therapeutic claim.